美国 · 股市与财经 · The Motley Fool

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

来源：The Motley Fool · 美国 12 小时前

Viking Therapeutics tested various doses of its leading anti-obesity candidate, VK2735, administered subcutaneously every other week or monthly (VK2735 also mimics the action of…

在 The Motley Fool 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

推荐阅读

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

分享

推荐阅读

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.